Welcome to Akesis Pharmaceuticals, Inc.™
Akesis Pharmaceuticals is an emerging metabolic disease company with a unique, patent-protected product that utilizes the insulin enhancing activity of vanadium, a naturally occurring micro-nutrient. In the last two decades clinical studies have shown that vanadium-containing products lower blood glucose levels in type 2 diabetes patients more substantially than many prescription drugs. Akesis’ management team is highly experienced in drug development and is leading the company in validating these findings, with the goal of offering unique FDA approved products to treat diabetes and other metabolic diseases that significantly impact public health. Akesis plans to develop AKP-020, its lead product, as a monotherapy within the $6 billion oral diabetes drug market.
Akesis Pharmaceuticals has an exceptional oral product candidate for the treatment of diabetes and related metabolic disorders. This product candidate is supported by issued and filed patents for both prescription and over-the-counter treatments. Data from multiple peer-reviewed publications have demonstrated that vanadium-containing compounds lower and help control blood glucose levels in patients with Type 2 diabetes. Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone. While diabetes is a national and international epidemic that is growing at an exponential rate and affects all racial and ethnic groups, the disease disproportionately affects particular minority populations. Akesis intends to include individuals of African American, Hispanic, Native American and Pacific Islander descent in the evaluation of its product candidates.
In the NewsAkesis Pharmaceuticals Names Christos Mantzoros, MD, DSc to its Scientific Advisory Board |
Essential ScienceAKP-020 is a novel vanadium compound that has shown considerable potential as a treatment for patients with type 2 diabetes. AKP-020 is anticipated to begin Phase 1b or 2a clinical trials after IND submission in 2007. |